[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
2. Nomura S, Ishii K, Inami N, Kimura Y, Uoshima N, Ishida H, Yoshihara T, Urase F, Maeda Y, Hayashi K: Evaluation of angiopoietins and cell-derived microparticles after stem cell transplantation. Biol Blood Marrow Transplant; 2008 Jul;14(7):766-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although stem cell transplantation (SCT) is being used for hematopoietic reconstitution following high-dose chemotherapy for malignancy, it involves certain serious transplant-related complications such as graft-versus-host disease (GVHD).
  • In addition, the elevation of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, and sIL-2 receptor (sIL-2R), which are GVHD markers after allogeneic SCT was observed.
  • The patients with high Ang-2 exhibited significant increase of sFasL and EDMP compared with those with low Ang-2.
  • In addition, the patients with high-grade GVHD exhibited a significant increase in Ang-2 compared to patients with low-grade GVHD.

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541195.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Fas Ligand Protein
  •  go-up   go-down


3. Atkins KA, Jeronimo J, Stoler MH, ALTS Group: Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study. Cancer; 2006 Aug 25;108(4):212-21
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study.
  • BACKGROUND: The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS) accumulated information regarding conventional and liquid-based Papanicolaou (Pap) cytology, 2 kinds of human papillomavirus (HPV) DNA testing, cervicography, and colposcopically directed biopsy.
  • The prevalence of squamous cell carcinoma in these women, the efficacy of tests, and the time to detection were reviewed.
  • All results of colposcopy, HPV testing, cytology, biopsies, and cervigrams were reviewed for all women in the ALTS trial who were diagnosed with squamous cell carcinoma.
  • RESULTS: There were 7 diagnoses of invasive cancer (all squamous cell) during the 2 years of the ALTS trial.
  • Although the enrollment studies isolated many high-grade lesions, none of those results were diagnostic of the underlying carcinoma.
  • CONCLUSIONS: The prevalence of squamous cell carcinoma in the setting of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology interpretation appears to be low (approximately 1 per 1000 women in the ALTS trial).
  • Type-specific testing identified HPV type 16 in 6 of 7 cancers and HPV type 18 in 1 of 7 cancers.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16680733.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / CN-55105; United States / NCI NIH HHS / CN / CN-55152; United States / NCI NIH HHS / CN / CN-55154; United States / NCI NIH HHS / CN / CN-55155; United States / NCI NIH HHS / CN / CN-55156; United States / NCI NIH HHS / CN / CN-55157; United States / NCI NIH HHS / CN / CN-55158; United States / NCI NIH HHS / CN / CN-55159
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


Advertisement
4. Fox PA, Nathan M, Francis N, Singh N, Weir J, Dixon G, Barton SE, Bower M: A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS; 2010 Sep 24;24(15):2331-5
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod.
  • OBJECTIVE: To determine whether imiquimod was more effective than placebo for the treatment of high-grade anal canal intraepithelial neoplasia (HG-ACIN).
  • METHODS: Sixty-four HIV-positive patients were randomized to self-application of imiquimod cream or matched placebo into the anal canal three times a week for 4 months.
  • Response was assessed by cytology, high-resolution anoscopy and biopsy 2 months after therapy.
  • All patients who failed to resolve were offered treatment with open-label imiquimod for a further 4 months.
  • RESULTS: Fifty-three patients completed the study, of which 28 patients were on active drug and 25 patients on placebo.
  • In the imiquimod group, four patients resolved and eight patients downgraded to low-grade squamous intraepithelial lesion (LSIL) with a median follow-up of 33 months.
  • Imiquimod was significantly associated with a positive outcome (P = 0.003).
  • Twenty-one patients entered a second open-label phase of treatment.
  • Five of these patients cleared their anal canal intraepithelial neoplasia (ACIN) and four patients downgraded to LSIL.
  • During this extended follow-up period, 61% have exhibited sustained absence of high-grade squamous intraepithelial lesion (HSIL).
  • CONCLUSION: This study demonstrates the effectiveness of imiquimod for the treatment of ACIN, and the benefit of prolonged or repeated treatments.
  • This form of therapy is likely to be especially valuable for patients with widespread multifocal ACIN who are otherwise difficult to treat, and should be considered as an adjunct to ablative therapy.
  • [MeSH-major] Aminoquinolines / administration & dosage. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. HIV Infections / drug therapy. HIV-1 / drug effects
  • [MeSH-minor] Administration, Cutaneous. Adult. Antiretroviral Therapy, Highly Active. Double-Blind Method. Homosexuality, Male. Humans. Male


5. Piketty C, Darragh TM, Heard I, Da Costa M, Bruneval P, Kazatchkine MD, Palefsky JM: High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis; 2004 Feb;31(2):96-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy.
  • BACKGROUND: The impact of highly active antiretroviral therapy (HAART) on the natural history of HPV infection and anal squamous intraepithelial lesions (SIL) in HIV-infected men who have sex with men (MSM) is poorly documented.
  • GOAL The goal of this study was to evaluate the prevalence of anal HPV infection and SIL inpatients under HAART.
  • Anal cytology was abnormal in 32 of 45 (71%) patients, including high-grade SIL in 10 patients (22%), low-grade SIL in 19 patients (42%), and atypical squamous cells of undetermined significance in 3 patients (7%).
  • The prevalence of anal SIL and HPV infection were similar in patients exhibiting a significant increase in CD4+ cell count after HAART initiation compared with those who did not.
  • CONCLUSION: Our results demonstrate a high prevalence of anal SIL, including high-grade SIL, and anal HPV infection in HIV-infected MSM despite immune restoration under HAART.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / epidemiology. HIV Infections / drug therapy. Neoplasms, Squamous Cell / epidemiology. Papillomavirus Infections / epidemiology. Tumor Virus Infections / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14743072.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01/101-RR-00079
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


6. Hubert P, Doyen J, Capelle X, Arafa M, Renoux V, Bisig B, Seidel L, Evrard B, Bousarghin L, Gerday C, Boniver J, Foidart JM, Delvenne P, Jacobs N: Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions. Am J Reprod Immunol; 2010 Aug 1;64(2):126-36
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions.
  • PROBLEM: Quantitative alterations of antigen-presenting cells (APC) in (pre)neoplastic lesions of the uterine cervix associated with human papillomavirus (HPV) infection suggest a diminished capacity to capture viral antigens and to induce a protective immune response.
  • METHOD OF STUDY: To test whether a cervical application of GM-CSF could restore an immune response against HPV in women with cervical low-grade squamous intraepithelial lesions (LSIL), we performed two clinical trials with 11 healthy women and 15 patients with LSIL.
  • All the HPV16(+) patients exhibited an immune response against HPV16 after GM-CSF applications, as shown by NK and/or T cells producing IFN-gamma whereas no cellular immune response was observed before the treatment.
  • Moreover, the anti-virus-like particles antibody titers also increased after the treatment.
  • CONCLUSION: These encouraging results obtained from a limited number of subjects justify further study on the therapeutic effect of APC in cervical (pre)neoplastic lesions.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Lymphocytes, Tumor-Infiltrating / drug effects. Neoplasms, Squamous Cell / drug therapy. Papillomavirus Infections / immunology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adaptive Immunity / drug effects. Administration, Topical. Adult. Antibodies, Viral / blood. Antigen-Presenting Cells / drug effects. Antigen-Presenting Cells / immunology. Cell Line. Cell Proliferation / drug effects. Female. Human papillomavirus 16 / drug effects. Human papillomavirus 16 / immunology. Human papillomavirus 16 / isolation & purification. Humans. Immunologic Factors / administration & dosage. Immunologic Factors / adverse effects. Immunologic Factors / pharmacology. Keratinocytes / drug effects. Lymphocyte Subsets / drug effects. Lymphocyte Subsets / immunology. Middle Aged. Natural Killer T-Cells / drug effects. Natural Killer T-Cells / immunology. T-Lymphocytes, Cytotoxic / drug effects. T-Lymphocytes, Cytotoxic / immunology. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367631.001).
  • [ISSN] 1600-0897
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Immunologic Factors; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


7. Robinson WR, Andersen J, Darragh TM, Kendall MA, Clark R, Maiman M: Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women. Obstet Gynecol; 2002 May;99(5 Pt 1):777-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women.
  • OBJECTIVE: To estimate the efficacy of isotretinoin for prevention of progression of low-grade squamous intraepithelial lesions (SIL) of the cervix to high-grade lesions or invasive cervical cancer; to estimate the regression rate of low-grade SIL with isotretinoin and the toxicity of isotretinoin in this setting; and to correlate serum CD4 levels with progression of low-grade SIL.
  • METHODS: A randomized, phase III, observation-controlled, multicenter trial was performed in which 117 human immunodeficiency virus (HIV)-positive women with low-grade SIL of the cervix received either oral isotretinoin at 0.5 mg/kg per day for 6 months or observation.
  • The primary endpoint was progression to high-grade SIL or cervical cancer.
  • RESULTS: Twenty-one of 102 women (20.6%) completing follow-up experienced progression to high-grade SIL, 13 in the observation group and eight in the isotretinoin group.
  • Baseline CD4 levels were lower than anticipated (median 329 cells/mm(3)), but not associated with time to progression (P =.36).
  • Most subjects (63 of 102, 61.7%) used highly active antiretroviral therapy.
  • CONCLUSION: Isotretinoin was not associated with longer time to progression of low-grade SIL.
  • This appears to be a chronic condition in HIV-positive women, with a low risk of progression and significant rate of resolution.
  • As in the general population, observation without excisional therapy may be appropriate for HIV-positive women with low-grade SIL.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. HIV Infections / complications. Isotretinoin / therapeutic use. Uterine Cervical Neoplasms / drug therapy


8. Shukla S, Bharti AC, Hussain S, Mahata S, Hedau S, Kailash U, Kashyap V, Bhambhani S, Roy M, Batra S, Talwar GP, Das BC: Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol; 2009 Dec;135(12):1701-9
Hazardous Substances Data Bank. QUININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions.
  • PURPOSE: 'Praneem', a polyherbal formulation developed by us, has successfully completed Phase II efficacy study for treatment of abnormal vaginal discharge due to reproductive tract infections that act as co-factors for HPV persistence.
  • In the present study we evaluated potential anti-HPV activity of Praneem in women infected with high risk HPV type 16.
  • METHODS: Twenty women molecularly diagnosed positive for HPV16 infection without or with low grade squamous intraepithelial lesion (LSIL) or inflammation were assigned to receive intra-vaginal, topical application of either Praneem tablet or placebo for 30 days excluding the days of menstrual period and were evaluated for persistence of HPV infection using HPV L1 consensus and HPV type 16-specific PCR as primary outcome.
  • RESULTS: One course of Praneem treatment resulted in elimination of HPV in 6 out of 10 (60%) cases.
  • A repeat treatment of four patients with persisting HPV infection resulted in clearance of HPV in two additional cases resulting in an overall 80% clearance of HPV 16 as against a spontaneous clearance of 10% (1/10) seen in the placebo arm.
  • CONCLUSION: Our results showed for the first time that a 30-day intra-vaginal application of the Praneem can result in elimination of HPV infection from the uterine cervix.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Human papillomavirus 16. Papillomavirus Infections / drug therapy. Plant Extracts / administration & dosage. Quinine / administration & dosage. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):485-90 [12814991.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(2):147-50 [12701965.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Mar;5(2):149-6 [15777222.001]
  • [Cites] Indian J Exp Biol. 1996 Jul;34(7):698-701 [8979510.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2009 Feb;103(2):167-72 [18990416.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71 [7658497.001]
  • [Cites] J Ethnopharmacol. 1997 Jan;55(2):133-9 [9032626.001]
  • [Cites] Immunol Cell Biol. 1997 Apr;75(2):190-2 [9107574.001]
  • [Cites] Chembiochem. 2004 Apr 2;5(4):408-21 [15185362.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1604-13 [12419786.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):196-200 [11812998.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1633-8 [10572150.001]
  • [Cites] Cancer Immunol Immunother. 2004 Jul;53(7):642-50 [14985860.001]
  • [Cites] Indian J Exp Biol. 1998 Nov;36(11):1151-3 [10085786.001]
  • [Cites] J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):230-9 [9486679.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1645-51 [12444178.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2005 Oct;99(10):769-74 [16084547.001]
  • [Cites] J Gen Virol. 1999 Feb;80 ( Pt 2):409-17 [10073701.001]
  • [Cites] Am J Reprod Immunol. 2000 Mar;43(3):144-51 [10735590.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Indian J Med Res. 2006 Apr;123(4):547-52 [16783046.001]
  • [Cites] PLoS Pathog. 2006 Jul;2(7):e69 [16839203.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2006 Dec;100(12):1164-7 [16750546.001]
  • [Cites] Int J Immunopharmacol. 1992 Oct;14 (7):1187-93 [1452404.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1250-7 [17060942.001]
  • [Cites] J Med Virol. 1992 Apr;36(4):239-45 [1315836.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):951-60 [15514944.001]
  • (PMID = 19526249.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Placebos; 0 / Plant Extracts; 0 / Praneem; 0 / Vaginal Creams, Foams, and Jellies; A7V27PHC7A / Quinine
  •  go-up   go-down


9. Scardamaglia P, Carraro C, Mancino P, Stentella P: [Effectiveness of the treatment with beta-glucan in the HPV-CIN 1 lesions]. Minerva Ginecol; 2010 Oct;62(5):389-93
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effectiveness of the treatment with beta-glucan in the HPV-CIN 1 lesions].
  • [Transliterated title] Efficacia del carbossimetilbetaglucano nella regressione delle alterazioni citologiche cervicali di basso grado HPV correlate.
  • AIM: The aim of the study was to evaluate the effectiveness of the beta-glucan in women with abnormal cytology, including the women with a positive screening for ASCUS-LSIL furtherly divided in women with positive cytology (ASCUS or LSIL) and negative colposcopy and women with abnormal cytology, positive colposcopy and human papilloma virus (HPV)-CIN1 hystology who opted for follow-up.
  • METHODS: From September 2007 to December 2008, 60 women with ASCUS-LSIL diagnosis were recruited at the ambulatory of Lasersurgery and Cervico-Vaginal Patology, Department of Gynecology and Obstetrics of Policlinico Umberto I of Rome.
  • 1) women with cytological diagnosis of ASCUS or LSIL and negative colposcopy;.
  • All the women were treated with two cycles of a daily topical application of beta-glucan for 20 consecutive days with a suspension of 10 days.
  • The effects of beta-glucan were analyzed with colposcopy and cytology at 3.6 and 12 months from the beginning of the therapy.
  • RESULTS: After 3 months of treatment, of the 30 women with positive cytology and negative colposcopy, 80% with ASCUS diagnosis resulted negative, 35% with LSIL diagnosis resulted negative; after 6 months 100% with ASCUS diagnosis resulted negative, 70% with LSIL diagnosis resulted negative; after 12 months 85% with LSIL diagnosis resulted negative.
  • For these women the definitive treatment was the TFD.
  • CONCLUSION: Our study demonstrate the effectiveness of the treatment with beta-glucan in the women with ASCUS-LSIL lesions and HPV-CIN1 lesions, increasing of the regressions rate after 12 months of the treatment of the 15-20%.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Papillomavirus Infections / drug therapy. Uterine Cervical Neoplasms / drug therapy. beta-Glucans / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20938424.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / beta-Glucans; 61163-25-5 / carboxymethyl-beta-1,3-glucan
  •  go-up   go-down


10. Berkova Z, Kaufmann RH, Unger ER, Reeves WC, Adam E: The effect of time interval between referral and colposcopy on detection of human papillomavirus DNA and on outcome of biopsy. Am J Obstet Gynecol; 2003 Apr;188(4):932-7
International Agency for Research on Cancer - Screening Group. diagnostics - Colposcopy and Treatment of Cervical Intraepithelial Neoplasia: A Beginner's Manual .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of time interval between referral and colposcopy on detection of human papillomavirus DNA and on outcome of biopsy.
  • OBJECTIVE: This study was undertaken to assess the effect of the time interval between referral cytology and the outcome of colposcopically directed biopsy in relation to human papillomavirus (HPV) DNA detected by polymerase chain reaction in women referred after abnormal Papanicolaou (Pap) smears.
  • STUDY DESIGN: The study enrolled 453 women who were referred for colposcopic examination after two Pap smears were reported as atypical squamous cells of undetermined significance (ASCUS) or low-grade intraepithelial lesions (LSIL) and 553 women who were referred with a single smear reported as high-grade squamous intraepithelial lesions (HSIL).
  • RESULTS: The results in both patient groups were evaluated in time intervals of 60 days or more, 61 to 120 days, and more than 120 days between referral and colposcopy.
  • Women of all race/ethnic backgrounds referred with HSIL were seen within 60 days in a significantly larger proportion than women referred with ASCUS/LSIL.
  • Women referred with ASCUS/LSIL had an increasing frequency of negative HPV findings with the prolonged time intervals.
  • In women referred with a single smear of HSIL, there was a significantly decreasing trend over time in detection of low-risk and unidentified types of HPV and an increasing trend of HPV DNA negative results.
  • CONCLUSION: The frequency of high-risk HPV DNA was similar in patients referred with ASCUS/LSIL or HSIL.
  • In both referral groups, there was a time-dependent increase of negative biopsy results and a decreased frequency of low-risk HPV or of unidentified HPV types.
  • This suggests that the initial abnormality on the Pap smear associated with other than high-risk HPV types may regress over time.
  • The presence of high-risk HPV DNA does not predict the actual histologically verifiable tissue changes but indicates a lower probability of negative biopsy results in all time intervals between referral and biopsy.
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Papanicolaou Test. Time Factors. Vaginal Smears

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12712088.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 200-92-0537
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


11. Stanley MA: Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res; 2002 Nov;89(2):241-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and new therapeutic approaches to cervical cancer.
  • Recent advances in the detection and therapy of carcinoma of the cervix and its squamous intra-epithelial precursor lesions exploit the knowledge that these lesions are a consequence of infection with high risk (HR) human papillomavirus (HPV).
  • Detection of HR HPV DNA in smears from selected patient groups will improve detection of high grade precursor lesions and immunodetection of the cell cycle dependent kinase inhibitor p16(INK4a) seems to specifically and sensitively identify HGSIL.
  • Immunisation with HPV early proteins has been shown to have both prophylactic and therapeutic efficacy in animal papillomavirus infections and immunotherapies for low grade intra-epithelial lesions are realistic.
  • Immunotherapies for HPV associated high grade pre-cancers and invasive cancers are problematic in view of tumour immune evasion.
  • [MeSH-major] Antiviral Agents / therapeutic use. Papillomaviridae / immunology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy. Viral Vaccines / therapeutic use
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / drug therapy. Cervical Intraepithelial Neoplasia / virology. Female. Genes, p16. Humans. Papillomavirus Infections / drug therapy. Prognosis. Tumor Virus Infections / drug therapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445663.001).
  • [ISSN] 0168-1702
  • [Journal-full-title] Virus research
  • [ISO-abbreviation] Virus Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Viral Vaccines
  •  go-up   go-down


12. Zanoschi Ch, Anton C, Anton E, Costăchescu G, Teleman S, Costăchescu G, Ciupilan I, Cărăuleanu M, Cărăuleanu A, Leica V, Pânzaru C, Grigore M, Merticaru I, Huianu O, Huianu L, Chifan M: [Cervugid ovules in cervico-vaginal infections and cervix uteri precancerous conditions treatment]. Rev Med Chir Soc Med Nat Iasi; 2004 Jul-Sep;108(3):628-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cervugid ovules in cervico-vaginal infections and cervix uteri precancerous conditions treatment].
  • This medicine was authorized by the National Drug Agency (ANM, Bucureşti) in 2001.
  • RESULTS AND DISCUSSION: Healing of the subjective symptoms in 98%, healing of the leukorrhea--as a main objective symptom--in 95%; The Bethesda system cytotest was one of the inflammatory type in the most of the cases and there wew found in 85 cases: 6 ASCUS, 41 LSIL, and 37 HSIL.
  • Cervugid may be considered as an important agent in the treatment of the precancerous affections af the cervix uteri on the following reasons: zhe cure of the infections caused by chlamydia, involved in the etiology of cervical neoplasms, the cure of the HPV infection under episome form, classified in the Bethesda system within the ASCUS, AGUS or LSIL classes.
  • In addition, it is active on chlamydia and mycoplasms, always sensitive to chloramphenicol therapy.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Chloramphenicol / therapeutic use. Hydrocortisone / analogs & derivatives. Metronidazole / therapeutic use. Nystatin / therapeutic use. Precancerous Conditions / drug therapy. Uterine Cervical Dysplasia / drug therapy. Uterine Cervicitis / drug therapy. Vaginitis / drug therapy
  • [MeSH-minor] Administration, Intravaginal. Adolescent. Adult. Aged. Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Antifungal Agents / therapeutic use. Antiprotozoal Agents / therapeutic use. Drug Combinations. Female. Humans. Middle Aged. Papanicolaou Test. Treatment Outcome. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginitis.
  • Hazardous Substances Data Bank. NYSTATIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. CHLORAMPHENICOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832988.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Antifungal Agents; 0 / Antiprotozoal Agents; 0 / Cervugid; 0 / Drug Combinations; 1400-61-9 / Nystatin; 140QMO216E / Metronidazole; 3X7931PO74 / hydrocortisone acetate; 66974FR9Q1 / Chloramphenicol; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


13. Buxant F, Bucella D, Anaf V, Simon P, Noël JC: Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Eur J Gynaecol Oncol; 2009;30(3):259-62
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix.
  • OBJECTIVES: Glucocorticoids (GCs) are used in cancer treatment to cause programmed cell death in transformed cells of the hematopoietic system and to lessen side-effects as nausea, vomiting, edema formation and allergies to specific chemotherapeutic agents.
  • Moreover, recently GCs were described as inhibitors of some chemotherapy or radiation-induced apoptosis.
  • METHODS: To clarify the issue, we tested by immunohistochemistry the expression status of GR in normal cervix epithelium (n = 30), in low-grade cervical intraepithelial neoplasia (LSIL) (n = 30), in high-grade cervical intraepithelial neoplasia (HSIL) (n = 30) and in invasive squamous cell carcinoma (ISCC) (n = 30).
  • All the patients with these lesions have a corresponding liquid-based cytology and were proved to be HPV-positive by using hybrid capture 2 methodology with probes against high-risk oncogenic HPvs. The evaluation of GR expression was performed by using the H-score system and an H-score > 50 was considered positive.
  • RESULT: GR expression was observed in normal epithelium, LSIL, HSIL and ISCC.
  • CONCLUSION: Because GCs could play a positive role in the progression of cancer, our demonstration of GR persistence in cervix cancer cells raises concern about the widespread combined use of GCs with antineoplastic drugs or agents in the clinical management of cervix cancer in women.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Receptors, Glucocorticoid / metabolism. Uterine Cervical Neoplasms / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697616.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Glucocorticoid
  •  go-up   go-down


14. Caprara L, Monari F, De Bianchi PS, Amadori A, Bondi A: [ASCUS in screening]. Pathologica; 2001 Dec;93(6):645-50
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The significance and use of the cytological diagnosis "atypical squamous cells of undetermined significance" (ASCUS) remain a major problem in cervical cancer screening.
  • The prevalence of diagnoses of low-grade squamous intraepithelial lesions (LG-SIL) decreased progressively with age while that of high-grade SIL was slightly higher between 30 and 39 years.
  • The observed peak reflects the prevalence of (1) cytological changes closely associated with perimenopausal age and at least compatible with the ASCUS diagnosis, and (2) cytological abnormalities induced by hormone replacement therapy.
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Epithelial Cells / drug effects. Epithelial Cells / ultrastructure. Estrogens / pharmacology. False Positive Reactions. Female. Hormone Replacement Therapy. Humans. Italy. Menopause. Middle Aged. Neoplastic Stem Cells / ultrastructure. Progesterone / pharmacology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


15. Ohno H, Ishikawa T, Kitajima H, Nomura S, Suzuki T, Konishi H, Ohno Y, Onishi R, Konaka Y, Arima N, Doi S, Nasu K, Takahashi T, Tsudo M, Fukuhara S, Uchiyama T: [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study]. Rinsho Ketsueki; 2002 Mar;43(3):170-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A multi-center series of 117 patients with malignant lymphoma were analyzed to evaluate the clinical significance of soluble interleukin-2 receptor alpha chain (sIL-2R alpha).
  • The initial levels of sIL-2R alpha ranged from 277 U/ml to 22,800 U/ml with a mean level of 3,451 +/- 4,268 U/ml and a median level of 1,600 U/ml.
  • The sIL-2R alpha levels of the diffuse lymphoma/intermediate-grade subtypes defined by the LSG classification/Working Formulation were higher than those of the follicular lymphoma/low-grade subtypes.
  • There was a tendency for B-cell lymphomas to show higher sIL-2R alpha levels than T-cell lymphomas.
  • The sIL-2R alpha level was correlated with the Ann Arbor clinical stage (I, II versus III, IV), presence or absence of B symptoms, and performance status (0, 1 versus 2, 3, 4) of the patients.
  • The sIL-2R alpha levels were in good accordance with the four risk groups defined by the International Prognostic Indices.
  • Of 21 patients whose tumor burden was serially measured, the coefficients of correlation between sIL-2R alpha and tumor mass were > 0.6 in 18 cases.
  • Sixty-two patients achieved complete remission (CR) during the study; the initial and minimum sIL-2R alpha levels were lower than those of the non-CR patients.
  • This study confirmed that sIL-2R alpha is a convenient and useful marker in the management of malignant lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Receptors, Interleukin-2 / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11979748.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Interleukin-2
  •  go-up   go-down


16. Malavazos AE, Corsi MM, Ermetici F, Coman C, Sardanelli F, Rossi A, Morricone L, Ambrosi B: Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. Nutr Metab Cardiovasc Dis; 2007 May;17(4):294-302
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Obesity can be considered a state of chronic, low-grade inflammation.
  • Particularly, visceral adipose tissue (VAT) seems to be an active compartment in pro-inflammatory molecule secretion.
  • METHODS AND RESULTS: Echocardiographic parameters, C-reactive protein (CRP), interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6-R), tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptor I (TNFR-I) were assessed in 27 normotensive obese women (age 33.3+/-8.3 years; BMI 43.5+/-4.8 kg/m2) and 15 normal-weight controls (age 36.8+/-8.2 years; BMI 22.6+/-1.7 kg/m2).
  • The obese patients had higher serum IL-6 (p<0.01), sIL-6-R (p<0.0001), sIL-6-R/IL-6 complex (p<0.05), TNF-alpha (p<0.02), sTNF-alpha-RI (p<0.03) and CRP (p<0.0001) levels than normal women.
  • Moreover, end-diastolic septum thickness (SW), end-diastolic posterior wall thickness (PW), absolute and indexed left ventricular mass, deceleration time (DT), myocardial performance index (MPI) and isovolumetric relaxation time (IVRT) were correlated with sIL-6-R, sIL-6-R/IL-6 complex and CRP levels.
  • Interestingly, sIL-6-R, sIL-6-R/IL-6 complex, CRP, SW, PW, DT and MPI were higher in patients with a VAT area >130 cm2 than those with <130 cm2.
  • CONCLUSION: In normotensive obese women several pro-inflammatory molecules correlate with both echocardiographic abnormalities and the amount of intra-abdominal fat; these results may support a role for visceral fat in predisposing to cardiac dysfunction, possibly through a low-grade state of inflammation.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434052.001).
  • [ISSN] 1590-3729
  • [Journal-full-title] Nutrition, metabolism, and cardiovascular diseases : NMCD
  • [ISO-abbreviation] Nutr Metab Cardiovasc Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines; 0 / Receptors, Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


17. Zhang WP, Wang JM, Ju XP, Song XM, Tong SP, Li HM: [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2003 Mar;24(3):129-33
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
  • OBJECTIVE: To analyze the incidence and the effective prevention and treatment of graft-versus-host disease (GVHD) for the allogeneic peripheral blood stem cell transplantation (allo-PBSCT) for the treatment of leukemia.
  • Two regimens were used for prophylaxis of GVHD: one was the combination of low dose cyclosporine (CsA, 2 - 3 mg x kg(-1) x d(-)1 i.v. or 4 - 6 mg x kg(-1) x d(-1) p.o.) and short course methotrexate (MTX, 15 approximately 10 mg, +1, +3, +6, +11 d) (CsA/MTX group, 32 patients), the other was short course of mycophenolate mofetil (MMF, 1.0 bid, +1 - +28 d) in addition to CsA and MTX (MMF/CsA/MTX group, 18 patients).
  • RESULTS: All patients were successfully engrafted and the median times to ANC > 0.5 x 10(9)/L and to platelet > 20 x 10(9)/L were 14 (10 - 22) and 20 (10 - 68) days post PBSCT respectively.
  • The incidence of acute GVHD (aGVHD) was 40% (20/50) and of grade III - IV was 12% (6/50).
  • Patients with aGVHD displayed significantly higher sIL-2R levels [(277.3 +/- 26.4) U/L] and CD(25)(+) cells [(8.1 +/- 3.4)%] than those without GVHD [(128.1 +/- 96.7) U/L and (3.6 +/- 1.7)%] (P < 0.05).
  • CONCLUSION: The incidence of aGVHD was low, but of cGVHD was high in allo-PBSCT. sIL-2R and CD(25)(+) cells after PBSCT may provide predictive markers for aGVHD.
  • [MeSH-major] Graft vs Host Disease / prevention & control. Leukemia / therapy. Mycophenolic Acid / analogs & derivatives. Peripheral Blood Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Cyclosporine / therapeutic use. Drug Therapy, Combination. Enzyme Inhibitors / therapeutic use. Female. Humans. Immunosuppressive Agents / therapeutic use. Male. Methotrexate / therapeutic use. Middle Aged. Transplantation Conditioning / methods. Transplantation, Homologous / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12697123.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Zák P, Chrobák L, Dĕdic K, Podzimek K: [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine]. Vnitr Lek; 2000 Oct;46(10):697-703
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
  • Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA) induces in 85% patients complete remission.
  • For detection of MRD the authors used immunohistochemical examination of bone marrow with DBA.44 antibodies.
  • The infiltration grade was examined on three areas of standard size (3 x 65,265 micron 2) and expressed in percent.
  • A total of 45 trepanobioptic specimens from 21 patients were examined who achieved after treatment with 2-CdA complete remission.
  • In all samples suitable for evaluation the presence of leukemic cells (MRD) was detected with a median of 3% and a range of 1% to 18%.
  • With induction of complete remission correlates also the low serum level of the soluble receptor for IL-2 (sIL-2R).
  • In a female patient after 24 months of treatment with 2-CdA the grade of leukemic infiltration rose from 1% to 12% and during the 36th month to 50% DBA.44+ leukemic cells.
  • The incipient relapse in this patient was not associated, despite marked infiltration of bone marrow, with failure of hematopoiesis and a marked rise of sIL-2R.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Cells / pathology. Cladribine / therapeutic use. Leukemia, Hairy Cell / drug therapy. Leukemic Infiltration

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11344629.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


19. Heard I, Potard V, Costagliola D: Limited impact of immunosuppression and HAART on the incidence of cervical squamous intraepithelial lesions in HIV-positive women. Antivir Ther; 2006;11(8):1091-6
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited impact of immunosuppression and HAART on the incidence of cervical squamous intraepithelial lesions in HIV-positive women.
  • BACKGROUND: Although highly active antiretroviral therapy (HAART) has lowered the incidence of various opportunistic diseases, its impact on cervical squamous intraepithelial lesions (SILs) is unclear.
  • Our objective was to compare the incidence of SILs in HIV-infected women receiving HAART versus those not receiving HAART and to determine the role of risk factors including immunosuppression in the pathogenesis of SIL.
  • METHODS: A total of 298 HIV-infected women with normal Papanicolaou (Pap) smear and normal colposcopic findings at enrollment were followed-up until incident SIL or last follow-up visit.
  • Cox regression modelling was used to assess risks factors for incident SIL.
  • RESULTS: Eighty-eight women developed SILs, including 75 low-grade lesions, during a median follow-up of 28 months (16-52; incidence of 8.7 cases per 100 person-years).
  • Incident SIL was not associated to low CD4+ T-cell count (P=0.54).
  • In multivariate analysis, the only significant risk factor for incident lesion was the age between 30-39 compared with over 40 (RR: 3.5; 95% CI: 1.4-8.9; P=0.02).
  • CONCLUSION: No impact in the development of SIL was evidenced for CD4+ T-cell counts, but we cannot exclude a modest impact of HAART.
  • All HIV-positive women should be offered to participate in cervical cancer screening programmes whether or not they receive effective antiretroviral therapy.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / epidemiology. HIV Infections / complications. HIV Infections / drug therapy. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302379.001).
  • [ISSN] 1359-6535
  • [Journal-full-title] Antiviral therapy
  • [ISO-abbreviation] Antivir. Ther. (Lond.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


20. Joshi J, Affandi MZ, Amin P, Vaidya R, Shah R: Persistence of cytologic abnormality after treatment of bacterial, parasitic and fungal infections in older women with low grade squamous intraepithelial lesion. Acta Cytol; 2010 Mar-Apr;54(2):242-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of cytologic abnormality after treatment of bacterial, parasitic and fungal infections in older women with low grade squamous intraepithelial lesion.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Uterine Cervical Dysplasia / drug therapy. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents / therapeutic use. Antifungal Agents / therapeutic use. Antiprotozoal Agents / therapeutic use. Female. Humans. Male. Middle Aged. Outcome Assessment (Health Care) / methods. Outcome Assessment (Health Care) / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391993.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Antifungal Agents; 0 / Antiprotozoal Agents
  •  go-up   go-down






Advertisement